A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

This Phase 1 study is testing a new experimental weight-loss medicine called NNC6989-0001 in healthy adults with overweight or obesity to assess its safety and tolerability. The drug has not yet been approved for prescription and is being studied in two parts — single doses and then multiple doses over time — with participants receiving either the medicine or a placebo. Non-pregnant adults aged 18 to 55 with a BMI between 25 and 35 (single dose) or 25 to 40 (multiple dose) who are otherwise healthy may be eligible, provided they have not recently used GLP-1 receptor agonist medications or undergone significant weight changes. Participation involves receiving injections of the medicine or placebo and attending clinic visits with blood tests and health monitoring throughout the study. This summary was prepared to help patients understand the study in plain language.